The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities

Molecular Pharmacology

Volumn 73, Issue 1, 2008, Pages 62-74

  Einstein, Monica ^a   Akiyama, Taro E ^a   Castriota, Gino A ^a   Wang, Chuanlin F ^a   McKeever, Brian ^a,b   Mosley, Ralph T ^a,c   Becker, Joseph W ^a   Moller, David E ^a,d   Meinke, Peter T ^a   Wood, Harold B ^a   Berger, Joel P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Vitae Pharmaceuticals Inc   (United States)

^c PHARMASSET INC   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TYROSINE;

ADIPOCYTE; ADIPOGENESIS; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION; WILD TYPE; X RAY CRYSTALLOGRAPHY;

EID: 37349060123     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041202     Document Type: Article

References (29)

1. Acton JJ 3rd, Black RM, Jones AB, Moller DE, Colwell L, Doebber TW, Macnaul KL, Berger J, and Wood HB (2005) Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg Med Chem Lett 15:357-362.
2. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, et al. (1999) Novel PPARγ and PPARδ ligands produce distinct biological effects. J Biol Chem 274:6718-6725.
3. Berger J and Moller DE (2002) The mechanism of action of PPARs. Annu Rev Med 53:409-435.
4. Berger JP, Akiyama TE, and Meinke PT (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26:244-251.
5. Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, Elbrecht A, Johnson BA, Zhou G, Doebber TW, et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated receptor [gamma] selective modulator. Mol Endocrinol 17:662-676.
6. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, et al. (1998) Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54:905-921.
7. Brünger AT, Kuriyan J, and Karplus M (1987) Crystallographic R-factor refinement by molecular dynamics. Science 235:458-460.
8. Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Marki HP, et al. (2006) A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 20:809-830.
9. Davis AM and Teague SJ (1999) Hydrogen bonding, hydrophobic interactions and failure of the rigid receptor hypothesis. Angew Chem Int Ed Engl 30:736-749.
10. Dropinski JF, Akiyama T, Einstein M, Habulihaz B, Doebber T, Berger JP, Meinke PT, and Shi GQ (2005) Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists. Bioorg Med Chem Lett 15:5035-5038.
11. Elbrecht A, Chen Y, Adams A, Berger J, Griffin P, Klatt T, Zhang B, Menke J, Zhou G, Smith RG, et al. (1999) L-764406 is a partial agonist of human peroxisome proliferator-activated receptor γ. The role of Cys313 in ligand binding. J Biol Chem 274:7913-7922.
12. Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, and Mutoh S (2006) A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J Pharmacol Exp Ther 318:863-871.
13. Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, and Xu HE (2000) Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 5:545-555.
14. Hunt CR, Ro JHS, Dobson DE, Min HY, and Spiegelman B (1986) Adipocyte P2 gene developmental expression and homology of 5′-flanking sequences among fat cellspecific genes. Proc Natl Acad Sci U S A 83:3786-3790.
15. Jiang HP and Serrero G (1992) Isolation and characterization of a full-length cDNA coding for an adipose differentiation-related protein. Proc Natl Acad Sci U S A 89:7856-7860.
16. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, and Law RE (2000) Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 401:259-270.
17. Liu K, Black RM, Acton JJ 3rd, Mosley R, Debenham S, Abola R, Yang M, Tschirret-Guth R, Colwell L, Liu C, et al. (2005) Selective PPARgamma modulators with improved pharmacological profiles. Bioorg Med Chem Lett 15: 2437-2440.
18. McRee DE (1999) XtalView/Xfit - A versatile program for manipulating atomic coordinates and electron density. J Struct Biol 125:156-165.
19. Miller CP (2002) SERMs: evolutionary chemistry, revolutionary biology. Curr Pharm Des 8:2089-2111.
20. Minoura H, Takeshita S, Ita M, Hirosumi J, Mabuchi M, Kawamura I, Nakajima S, Nakayama O, Kayakiri H, Oku T, et al. (2004) Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. Eur J Pharmacol 494:273-281.
21. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, and Milburn MV (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395: 137-143.
22. Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, et al. (1999) A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A 96:6102-6106.
23. Ostberg T, Svensson S, Selen G, Uppenberg J, Thor M, Sundbom M, Sydow-Backman M, Gustavsson AL, and Jendeberg L (2004) A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem 279:41124-41130.
24. Otwinowski Z and Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
25. Sack JS (1988) CHAIN-a crystallographic modeling program. J Mol Graph 6:224-235.
26. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54:3442-3452.
27. Sheu SH, Kaya T, Waxman DJ, and Vajda S (2005) Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry 44:1193-1209.
28. Shi GQ, Dropinski JF, McKeever BM, Xu S, Becker JW, Berger JP, MacNaul KL, Elbrecht A, Zhou G, Doebber TW, et al. (2005) Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. J Med Chem 48:4457-4468.
29. Tontonoz P, Hu E, Devine J, Geale EG, and Spiegelman BM (1995) PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 15:351-357.